Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Practical Resource for Nurses

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Practical Resource for Nurses 2021 Original pdf

Please log in to view product prices.

AUTHORS: Buka, Richard J. (Birmingham) Moloney, Dee (London)
Category:

Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A Practical Resource for Nurses 2021 Original pdf

Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine.

AUTHORS: Buka, Richard J. (Birmingham) Moloney, Dee (London)

PAGES: 96

YEAR: 2021

PUBLICATION: karger

LANGUAGE: English

Related Products